Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK2 | Q9HBH9 | 7/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL27463691 | 0.83 | PI4KA (0.39) | MKNK2IRAK4PRMT5WDR77MKNK1 | |
| SCHEMBL24109829 | 0.78 | MTNR1A (0.47) | — | |
| SCHEMBL24110589 | 0.77 | RPS6KA5 (0.36) | EGFR | |
| SCHEMBL5068124 | 0.76 | MKNK2 (0.42) | MKNK2EGFRPRMT5WDR77MKNK1 | |
| SCHEMBL24110604 | 0.76 | HTR2C (0.47) | MKNK2EGFR | |
| SCHEMBL24110588 | 0.75 | MAPT (0.37) | PRMT5DGAT1 | |
| SCHEMBL24109830 | 0.75 | KDR (0.40) | — | |
| SCHEMBL24110362 | 0.73 | MKNK2 (0.36) | MKNK2EGFRIRAK4PRMT5WDR77 | |
| SCHEMBL25299990 | 0.73 | MKNK2 (0.36) | MKNK2EGFRIRAK4PRMT5WDR77 | |
| SCHEMBL30404154 | 0.73 | MKNK2 (0.36) | MKNK2EGFRIRAK4PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| WO-2021252692-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | GAP43, SLC18A2, PNMT | MKNK2 1523/4885EGFR 4389/4885IRAK4 4512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.